Risk factors for and management of post-transplantation cardiovascular disease

BioDrugs

Volumn 15, Issue 4, 2001, Pages 261-278

  Fellström, Bengt ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM ANTAGONIST; CARVEDILOL; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; LISINOPRIL; METFORMIN; MIBEFRADIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC ACID; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; PREDNISONE; RAPAMYCIN; SULFONYLUREA DERIVATIVE; TACROLIMUS;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GRAFT FAILURE; GRAFT REJECTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MYOPATHY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0034789734     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115040-00006     Document Type: Review

References (138)

1. Foley RN, Parfrey PS, Sarnak MJ, Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 Suppl. 3: SI 12-9
2. Kasiske BL, Guijarro C, Massy ZA, el al, Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7; 158-65
3. Johnson DW, Herzig K, Purdie D, et al. A comparison of the effects of dialysis and renal transplantation on the survival of older urémie patients. Transplantation 2000; 69: 794-9
4. Rabhat CO, Thorpe KE, Russell JD, et al. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000; 11; 917-22
5. Schaubel D, Desmeules M, Mao Y, et al. Survival experience among elderly end-stage renal disease patients. A controlled comparison of transplantation and dialysis. Transplantation 1995; 60:1389-94
6. Cosio FG, Alamir A, Yim S, et al, Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 1998:53:767-72
7. Kavanagh D, Morris S, Northridge DB, et al. Electrocardiogram and outcome following renal transplantation. Nephron 1999:81: 109
8. Lindholm A, Albrechtsen D, Frödin L, et al, Ischémie heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451-7
9. USRDS Annual Report, Chapter 6: causes of death. Ann Arbor. Ml: USRDS, 1999: 89-100. Available from: URL: http://www.usrds.org
10. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906
11. Jardine AG, Pretransplant management of end-stage renal disease patients to minimize posttransplant risk. Transplantation 2000; 70 (11 Suppl.): SS46-50
12. De Lemos JA, Hulls LD, Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol 1996; 7: 2044-54
13. Shepherd J, Cobbe SM, Ford I, et al, Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group, n Eng J Med 1995; 333 (20): 1301-7
14. Kasiske BL, Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998: 32 Suppl. 3: S142-56
15. Jindal RM, Post-transplant hyperlipidaemia. Postgrad Med J 1997; 73: 785-93
16. Keane WF, Derangement of lipid metabolism and its management in renal transplant patients. Miner Electrolyte Metab 1997:23: 166-9
17. Aakhus S, Dahl K, Wideroe TE, Hyperlipidaemia in renal transplant patients. J Intern Med 1996; 239: 407-15
18. Segoloni GP, Triolo G, Cassader M, et al. Dyslipidemia in renal transplantation: a 3-year follow-up. Transplant Proc 1993:25: 2178-9
19. Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soe Nephrol 1995; 5: 2073-81
20. Jung K, Scheifler A, Blank W, et al, Changed composition of high-density lipoprotein subclasses HDL2 and HDL3 after renal transplantation. Transplantation 1988; 46: 407-9
21. Kasiske BL, Urnen AJ, Persistent hyperlipidemia in renal transplant patients. Medicine (Baltimore) 1987; 66: 309-16
22. Rao VK, Posttransplant medical complications. Surg Clin North Am 1998:78: 113-32
23. Hilbrands LB, Demacker PN, Hoitsma AJ. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993: 341 : 765-6
24. Brown JH, Anwar N. Short CD, et al. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporine monotherapy. Nephrol Dial Transplant 1993; 8: 863-7
25. Ghanem H, van den Dorpel MA, Weimar W, et al, Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 1996; 49: 488-93
26. Sutherland WH, Walker RJ, Ball MJ, et al. Oxidation of low density lipoproteins from patients with renal failure. Kidney Int 1995:48:227-36
27. Apanay DC, Neylan JF. Ragab MS, et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994: 58: 663-9
28. Dasgupta K, Powell D, Saldana S, et al. Elevated Hpid peroxidation products and depleted transferring levels in the plasma of kidney transplant recipients. Life Sei 1990: 46: 67-72
29. Kasiske B, Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1998; 84: 985-92
30. Aakhus S, Dahl K, Wideroe TE, Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14:648-54
31. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclsoporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37-43
32. Stegall MD, Wachs ME, Everson G, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64: 1755-60
33. Jindal RM, Sidner RA, Hughes DA, et al, Metabolic problems in recipients of liver transplants. Clin Transplant 1996; 10: 213-7
34. Hricik DE, Bartucci MR, Mayes JT, et al, The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992:54:868-71
35. Lopez-Miranda J, Perez-Jimenez F, Torres A, et al. Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992; 25: 379-86
36. Raine AE, Carter R, Mann JI, et al, Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 1988; 3: 458-63
37. Ballantyne CM, Podet EJ, Patsch WP, et al, Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53-6
38. Schorn TF, Kliem V, Bojanovski M, et al, Impact of long-term immunosuppression with cyclosporine A on serum lipids in stable renal transplant recipients. Transplant Int 1991 ; 4: 92-5
39. Donahoo WT, Kosmiski LA, Eckel RH, Drugs causing dyslipoproteinemia. Endocrinol Metab Clin North Am 1998: 27: 677-97
40. van den Dorpel MA, Ghanem H, Rischen-Vos J, et al, Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 1997;51:1608-12
41. Satterthwaite R, Aswad S, Sunga V, et al, Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 1998; 65:446-9
42. Jensik SC, Tacrolimus (FK506) in kidney transplantation: threeyear survival results of the US multicenter, randomized, comparative trial. FK506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1216-8
43. Claesson K, Mayer AD, Squifflet J-P, et al, Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporine A patients. Transplant Proc 1998; 30: 1292-4
44. Pirsch JD, Miller J, Deierhoi MH, et al, A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-83
45. Margreiter R, A prospective, randomized, multicentre study to compare the efficacy and safety of tacrolimus and ciclosporinmicroemulsion in renal transplantation. European Tacrolimus vs Ciclosporin-Microemulsion Renal Transplantation Study Group. Transplantation 2000; 69 Suppl.: S112
46. Johnson C, Ahsan N, Gonwa TA, et al, Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000: 69: 834-41
47. Friemann S, Stopp K, Christi R, et al. Conversion to taerolimus in hyperlipidemie patients. Transplant Proc 1999; 31 Suppl. 7A:4IS-3S
48. Short CD, Johnson RWG, Roberts IDS, Two years of taerolimus monotherapy following renal transplantation [abstract]. 4th International Conference on New Trends in Clinical and Experimental Immunosuppression; 2000: 154
49. Bos JD, et al, A European, multicenter, randomized, doubleblind study to evaluate the safety and efficacy of FK506 (taerolimus) in the treatment of severe, recalcitrant plaquetype psoriasis. Skin Pharmacol 1995; 8: 74
50. Fujisawa, Laboratory: blood chemistry. Report No.: FG-94506-02. Supplementary Appendix 7. (Data on file)
51. Caldwell J, Efficacy of FK506 in rheumatoid arthritis (RA): dose-ranging study in RA patients failing methotrexate (MTX) [abstract]. 4th International Conference on New Trends in Clinical and Experimental Immunosuppression: 2000: 153
52. Fujisawa, Chemistry parameters. Report No.: L1999000037: 45-50 (Data on file)
53. Abouljoud MS, Levy MF, Klintmalm GB, Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine US Multicenter trial. US Multicenter Study Group. Transplant Proc 1995; 27: 1121-3
54. Jindal RM, Popescu I, Emre S, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 1994; 57: 1395-8
55. Groth CG, Backman L, Morales JM, et al, Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-42
56. Kahan BD, Podbielski J, Napoli KL. et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-6
57. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus taerolimus/ prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67: 411-5
58. Ducloux D, Fournier V, Bresson-Vautrin C, et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity. A preliminary report. Transplantation 1998:65: 1504-6
59. Wierzbicki AS, The role of lipid lowering in transplantation. Int JClinPract 1999:53:54-9
60. Tonstad S, Holdaas H, G0rbitz C. et al. Is dietary intervention effective in posttransplant hyperlipidemia? Nephrol Dial Transplant 1995; 10: 82-5
61. Älvarez ML, Errasti P, Gômez G, et al, Effect of atorvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplant Proc 1999; 31: 2328-9
62. Pflugfelder PW, Huff M, Oskalns R, et al, Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995; 14:613-22
63. Boissonnat P, Salen P, Guidollet J, et al, The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemie heart transplant recipients. Transplantation 1994; 58: 245-7
64. Lal SM, Hewett JE, Petroski GF, et al, Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labelled crossover trial. Am J Kidney Dis 1995; 25: 616-22
65. Kato T, Tokoro T, Namii Y, et al, Early introduction of HMGCoA reductase inhibitors could prevent the incidence of transplant coronary artery disease. Transplant Proc 2000:32: 331-3
66. Kohashigawa JA, Katznelson S, Laks H, et al, Effect of pravastatin on outcomes after cardiac transplantation. N Engl JMed 1995:333:621-7
67. Wenke K, Meiser B, Thiery J, et al, Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997:96: 1398-402
68. Suliman ME, Qureshi AR, Barany P, et al, Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Im 2000; 57: 1727-35
69. Arnadottir M, Hultberg B, Wahlberg J, et al, Serum total homocysteine concentration before and after renal transplantation. Kidney Int 1998:54: 1380-4
70. Cole DE, Ross HJ, Evrovski J, et al, Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant récipients. Clin Chem 1998; 44: 2307-12
71. Bostom AG, Gohh RY, Beaulieu AJ, et al. Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. Transplantation 1999; 68: 257-61
72. Bostom AG, Shemin D, Gohh RY, et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int 2001; 59: S246-52
73. Cook RC, Tupper JK, Parker S, et al. Effect of immunosuppressive therapy, serum creatinine and time after transplantation on plasma total homocysteine in patients following heart transplantation. J Heart Lung Transplant 1995; 18 (5): 420-4
74. Arnadottir M, Hultberg B, Vladov V, et al. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996:61:509-12
75. Fernandez-Miranda C, Gomez P, Diaz-Rubio P, et al, Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin Transplant 2000; 14 (2): 110-4
76. Ducloux D, Motte G, Challier B. et al. Sérum total homocysteine and cardiovascular disease occurrence in chronic stable renal transplant recipients: a prospective study. J Am Soc Nephrol2000; 11: 134-7
77. Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997; 127: 1089-92
78. Bostom AG, Shemin D, Gohh RY, et al. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation 2000; 69 (10): 2128-31
79. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000:57: 307-13
80. Arend S, Mallat M, Westendorp R, et al. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997: 12: 1672-9
81. Opelz G, Wujciak T, Ritz E, Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217-22
82. Zeier M, Mandelbaum A, Ritz E, Hypertension in the transplanted patient. Nephron 1998; 80: 257-68
83. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182-93
84. Midtvedt K, Hartmann A, Bentdal 0, et al, Bilateral nephrectomy simultaneously with renal allografting does not alleviate hypertension 3 months following living-donor transplantation. Nephrol Dial Transplant 1996; 11: 2045-9
85. Ferez Fontân M, Rodrîguez-Carmona A, Garcia Falcon T. et al. Early immunologie and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis 1999:33:21-8
86. Budde K, Waiser J, Pritsche L, et al, Hypertension in patients after renal transplantation. Transplant Proc 1997; 29: 209-11
87. Brown MJ, Haydock S, Pathoaetiology, epidemiology and diagnosis of hypertension. Drugs 2000; 59 Suppl. 2: 1-12
88. Aakhus S, Dahl K, Wideroe TE, Cardiovascular morbidity and mortality in renal transplant recipients. Results from a 5 year follow-up [abstract no. A231]. Nephrol Dial Transplant 1997; 12
89. Curtis JJ, Posttransplant hypertension. Transplant Proc 1998; 30:2009-11
90. Morrison RJ, Short HD, Noon GP. et al. Hypertension after lung transplantation. J Heart Lung Transplant 1993; 12: 928-31
91. Grossman RM, Chevret S, Abi-Rached J, et al, Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132 (6): 623-9
92. Van Joost T, Bos JD, Heule F, et al. Low dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol 1988: 118(2): 183-90
93. Fry L, Psoriasis: immunopathology and long-term treatment with cyclosporin. J Autoimmun 1992; 5 Suppl. A: 277-83
94. Bartholomeusz B, Hardy KJ, Nelson AS, et al, Modulation of nitric oxide improves cyclosporine A-induced hypertension in rats and primates. J Hum Hypertens 1998; 12: 839-44
95. Farge D, Julien J, Effects of transplantation on the renin angiotensin system (RAS). J Hum Hypertens 1998; 12: 827-32
96. Henry ML, Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999: 13: 209-20
97. Pirsch JD, Tacrolimus versus cyclosporine in kidney transplantation: five-year survival results of the US multicenter, randomized, comparative study. FK506 Kidney Transplant Study Group. Transplantation 2000; 69 Suppl.: SI 13
98. Jurewicz WA, Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. Transplant Proc 1999:31 Suppl.7A: 64S6S
99. van Riemsdijk 1C, Baan CC, Mol WM, et al, Conversion from cyclosporine to tacrolimus improves blood pressure and cholesterol levels in heart transplant recipients without affection the TGF- system. Am soc Transpl 2000; Abstract A698
100. Vanrenterghem YFC, Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine? Curr Opin Nephrol Hypertens 1999: 8: 669-74
101. Veenstra DL, Best JH, Hornberger J, et al. Incidence and longterm cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33 (5): 829-39
102. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588-92
103. Schulak JA, Hricik DE, Steroid withdrawal after renal transplantation. Clin Transplant 1994; 8: 211-6
104. Rao VK, Posttransplant medical complications. Surg Clin North Am 1998:78: 113-32
105. Olyaei AJ, deMattos AM, Bennett WM, A practical guide to the management of hypertension in renal transplant recipients. Drugs 1999; 58: 1011-27
106. Midtvedt K, Hartmann A, Foss A, et al, Improved long-term graft function and fewer rejection episodes in hypertensive renal transplant patients treated with nifedipine as compared to lisinopril (abstract no. A3728].J Am Soc Nephrol 1999; 10
107. Mourad G, Ribstein J, Mimran A, Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43 (2): 419-25
108. Hébert MF, Lam AY, Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999 Jun; 33 (6): 680-2
109. Krahenbuhl S, Menafoglio A. Giostra E, et al. Serious interaction between mibefradil and tacrolimus. Transplantation 1998; 66: 1113-5
110. Ocran KW, Plauth M, Mai I, et al. Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation. Z Gastroenterol 1999; 37: 1025-8
111. Seifeldin RA, Marcos-Alvarez A, Gordon FD, et al, Nifedipine interaction with tacrolimus in liver transplant recipienls. Ann Pharmacother 1997; 31: 571-5
112. Iwasaki K, Matsuda H, Nagase K, et al, Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993:82: 209-16
113. Brockmoller J, Neumayer HH, Wagner K, et al. Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 1990; 38 (3): 237-42
114. Kaijser M, Johnsson C, Zezina L, et al. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant 1997; 11: 577-81
115. Elliott WJ, Traditional drug therapy of hypertension in transplant recipients. J Hum Hypertens 1998; 12: 845-9
116. Hernandez D, Lacalzada J, Salido E, et al, Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000; 58: 889-97
117. Schmieder RE, Martus P, Klingbeil A, Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-13
118. Zezina L, Larssen E, Fellström B, Candesartan cilexitil reduces graft arteriosclerosis in aortic transplantation model in rat. Transpl Immunol 2001. In Press
119. Jindal RM, Sidner RA, Milgrom ML, Post-transplant diabetes mellitus: The role of immunosuppression. Drug Saf 1997: 16: 242-57
120. Jindal RM, Posttransplant diabetes mellitus -a review. Transplantation 1994:58: 1289-98
121. Boudreaux JP, McHugh L, Canafax DM, et al, The impact of cyclosporine and combination immunosuppression on the incidence of post-transplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376-81
122. Hathaway DK, Tolley EA, Blakely ML, et al, Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 1993; 7: 330-8
123. Arner P, Gunnarsson R, Blomdahl S, et al. Some characteristics of steroid diabetes - a study in renal transplant recipients receiving high dose corticosteroid therapy. Diabetes Care 1983; 6:23
124. Jindal RM, Dubernard J-M, Towards a specific immunosuppression for pancreas and islet grafts. Clin Transplant 2000; 14: 242-5
125. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 2000; 23 Suppl. 1 : S4
126. Miles AM V, Sumrani NB, Horowitz R, et al, Diabetes after renal transplantation. As deleterious as non-transplant-associated diabetes? Transplantation 1998; 65: 380-4
127. Friedman EA, Shyh TP, Beyer MM, et al, Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985: 5: 196-202
128. Després J-P, Lamarche B, Mauriège P, et al, Hyperinsulinemia as an independent risk factor for ischémie heart disease. N EnglJMed 1996:334:952-7
129. Pyörälä M, Miettinen H, Laakso M, et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policeman Study. Circulation 1998; 98: 398-404
130. Kneteman NM, Lakey JRT, Wagner T, et al, The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 1996:61: 1206-10
131. Hjelmessth J, Hartmann A, Kofstad J, et al, Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-83
132. Hricik DE, Bartucci MR, Moir EJ, et al, Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporinetreated renal transplant recipients. Transplantation 1991; 51: 374-7
133. Weir MR, Fink JC, Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999:34: 1-13
134. Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318: 1104-7
135. Morris-Stiff G, Prospective randomized study comparing FK506 (Prograf) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. Transplant Proc 1999; 30: 288-92
136. Miller J, Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69: 875-80
137. Forsythe J, Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. European Multicentre Tacrolimus/MMF Study Group. Transplant Proc 1999; 31 Suppl.7A:69S-71S
138. Jordan ML, Naraghi R, Shapiro R, et al, Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc 1998; 30: 1257-60